Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Interest Expenses (2020 - 2026)

Cytek Biosciences filings provide 6 years of Interest Expenses readings, the most recent being -$725000.0 for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 87.78% to -$725000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $474000.0, a 109.05% increase, with the full-year FY2025 number at $474000.0, up 109.05% from a year prior.
  • Interest Expenses hit -$725000.0 in Q4 2025 for Cytek Biosciences, down from $494000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $687000.0 in Q4 2022 to a low of -$5.9 million in Q4 2024.
  • Median Interest Expenses over the past 5 years was $437000.0 (2021), compared with a mean of $81000.0.
  • Biggest five-year swings in Interest Expenses: surged 43200.0% in 2021 and later tumbled 1605.84% in 2024.
  • Cytek Biosciences' Interest Expenses stood at $492000.0 in 2021, then skyrocketed by 39.63% to $687000.0 in 2022, then plummeted by 42.65% to $394000.0 in 2023, then tumbled by 1605.84% to -$5.9 million in 2024, then skyrocketed by 87.78% to -$725000.0 in 2025.
  • The last three reported values for Interest Expenses were -$725000.0 (Q4 2025), $494000.0 (Q3 2025), and $414000.0 (Q2 2025) per Business Quant data.